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ABSTRACT
 مفلا  قيرط نع تانوردنيللأاب  جلاعلا  ةيلاعف  مييقتل   :فادهلأا
.يديرولا نقلحا قيرط نع تانورديلوزلاب جلاعلا عم ةنراقم
 HNS ستراب يف ةيعلاطتسلاا ةساردلا هذه تيرجُأ  :ةقيرطلا
 ينب  تنراق  ةساردلا  .م2012  سرامو  م2010  ليربأ  ينب  Trust
 ضيرم  234  يف  )BMD(  ماظعلا  نداعم  ةفاثك  يف  تاريغتلا
 :تانيفسوفسيبلا  نم  ينعونب  مهجلاع  تم  ماظعلا  ةشاشهب
 نع ًايونس ذخؤي تانورديلوزلاو مفلا قيرط نع ذخؤي تانوردنيلأ
 قيرط نع تانوردنيلأ ًاضيرم 118 ىقلت .يديرولا نقلحا قيرط
 .تانورديلوزلاب ضيرم 116 جلاع تم امنيب عوبسلأاب غلم 70 مفلا
 تاريغتلا سايقل )DEXA( ماظعلا ةفاثك سايق ةعشأ تمدختُسا
 نم  يفللخا-يماملأا  ءزلجاو  رسيلأا  ذخفلا  يف  ماظعلا  ةفاثك  يف
 ةنس دعبو جلاعلا لبق )L1-L4 ةينطقلا تارقفلا( يرقفلا دومعلا
 .جلاعلا نم نیتنس مث
 تارقفلا يف ماظعلا ةفاثك نأ ىلع لایلد ةساردلا مدقت  :جئاتنلا
 عم  ةنراقم  نیتنس  دعب  5.7%و  3.6%  ةبسنب  تدادزا  ةینطقلا
 تانوردنیللاأ نوقلتي نيذلا ىضرلما يف جلاعلا لبق ةیساسلأا میقلا
 رسيلأا ذخفلا يف ماظعلا ةفاثك عومجم ضفخنا ،تانوردیلوزلاو
 .يلاوتلا ىلع )p=0.001( ةبسنب تانوردنیلأب جلاعلما ضيرلما يف
 جلاعلما ضيرلما يف رسيلأا ذخفلا يف ماظعلا ةفاثك عومجم ضفخنا
 نيذلا  ىضرلما  يف  تدادزا  نكلو  0.4%  ةبسنب  تانوردنیلأب
.)p=0.0001( 0.8% ةبسنب تانوردیلوز نوقلتي
 ىلع  قوفتم  تانوردیلوزلا  نأ  ةساردلا  هذه  تبثُت   :ةتمالخا
 ماظعلا ةشاشه نم نوناعي نيذلا ىضرلما جلاع يف تانوردنيللأا
 يف  مفلا  قيرط  نع  تانیفسوفسیبلا  .ةيبناج  ضارعا  نود  نم
 .ماظعلا ةشاشه نم نوناعي نيذلا ىضرلما يف ماظعلا ةفاثك نیستح
 لثمتت  ةیفاضإ  ةزیم  تانوردیلوزلل  نأ  ودبي  ،كلذ  ىلع  ةولاع
 للاتخلاا نم نوناعي نيذلا ىضرلما يف ةلضفلما ناملأا ةروص يف
.مفلا قيرط نع تانیفسوفسیبلا نم يمضهلا
Objectives: To evaluate the efficacy of orally-
administered alendronate compared with 
intravenously-administered zoledronate.
Methods: This prospective study was carried out at 
Barts Health HNS Trust between April 2010 and 
March 2012. This study compares changes in bone 
mineral density )BMD( in 234 patients treated with 
2 bisphosphonates: alendronate taken orally, and 
zoledronate administered intravenously. One hundred 
and eighteen patients received alendronate at 70 mg/
week, while 116 patients received zoledronate once 
annually. Dual energy x-ray absorptiometry was used 
to measure BMD of the left hip and anterior-posterior 
spine )lumbar L1-L4( skeletal sites at baseline, and at 
one-, and 2-years post-treatment. 
Results: This study provides evidence that lumbar 
spine BMD increased by 3.6% in patients receiving 
alendronate, and 5.7% in patients receiving 
zoledronate after 2 years compared with baseline 
values )p=0.0001 for both(. Total hip BMD decreased 
in patients treated with alendronate by 0.4% but 
increased in patients receiving zoledronate by 0.8% 
)p=0.0001(. 
Conclusion: This study provides evidence that 
zoledronate is more effective than alendronate in treating 
patients with osteoporosis and with no gastrointestinal 
)GI( serious side effects. Furthermore, zoledronate 
appears to have the added advantage of a better safety 
profile in patients suffering from GI intolerance of oral 
bisphosphonates.
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Osteoporosis is a disease characterized by low bone mass and micro-architectural deterioration 
of associated tissue.1,2 It is estimated that over 200 
million people worldwide have the disease,3 and suffer 
clinical consequences, including increased incidence of 
bone fractures, morbidity, and premature mortality.2,3 
Approximately 30% of all post-menopausal women 
suffer from osteoporosis.3 The importance of developing 
treatment strategies that reduce the risk of fracture is 
therefore, evident both from individual and societal 
perspectives. Treatment with nitrogen-containing 
bisphosphonates, a class of potent therapeutic agents 
that inhibit osteoclast-mediated bone resorption, 
is one of the major pharmacological interventions 
for osteoporosis.4-8 The primary therapeutic goal of 
treatment with bisphosphonates is to reduce fracture 
risks.9 In placebo-controlled clinical trials, the efficacy 
of bisphosphonates in improving bone mineral density 
)BMD( at key skeletal sites, particularly at the lumbar 
spine has been demonstrated.10-12 When compared 
with placebo, all bisphosphonate formula at different 
dose levels, routes, and frequency of administration 
significantly increased BMD. In 2012, the Agency for 
Healthcare Research and Quality )AHRQ( published an 
update following a systematic review of the comparative 
effectiveness of treatments for osteoporosis.13 The 
AHRQ report provided evidence for decreased risk of 
hip and other non-vertebral fractures in alendronate-, 
risedronate- and zoledronate-treated patients even in 
high-risk post-menopausal women.13 As pharmaceutical 
agents, however, bisphosphonates can cause a number 
of adverse events, including some that are attributed to 
mode of administration. For example, gastrointestinal 
)GI( complaints, such as dysphagia, esophagitis, and 
esophageal and gastric ulcers are seen predominantly 
with orally-administered bisphosphonates, such as 
alendronate, risedronate, and ibandronate.7,8,14-18 In 
randomized clinical trials of alendronate involving 
large cohorts of patients, high incidences of upper 
GI complaints, such as dyspepsia were reported.19-21 
However, prospective studies involving untreated 
osteoporosis patients to compare therapeutic efficacy 
and side effects of different bisphosphonates are limited. 
Intravenous bisphosphonates may be followed by an 
acute-phase reaction within one to 3 days of infusion, 
characterized by low-grade temperature, and muscle 
and joint pain. The current study was carried out to 
evaluate the efficacy of orally-administered alendronate 
compared with intravenously-administered zoledronate. 
Our starting hypothesis was that zoledronate would 
be as effective as alendronate but with no, or fewer, 
GI-associated adverse events. Changes in lumbar spine 
and hip BMD in patients with osteoporosis receiving 
either a single intravenous )i.v.( dose of zoledronate 
at 5 mg/year, or oral alendronate at 70 mg/week in a 
clinical setting were compared. 
Methods. A cohort of 234 patients attending 
the osteoporosis clinics at the Royal London and St 
Bartholomew’s Hospitals, Barts Health HNS Trust 
between April 2010 and March 2012 was recruited 
for the study. For recruitment, patients had to have 
a T score of at least minus 2.0 )-2.0( at the lumbar 
spine, or the total hip as measured by dual energy 
x-ray absorptiometry )DEXA( scan. Patients who were 
bedridden, had diabetes mellitus, renal disease, cancer, 
or were receiving steroids were excluded from the study. 
One hundred and eighteen of the 234 recruited patients 
received alendronate )70 mg/week( taken orally, while 
116 patients received 5 mg/year zoledronate once a year 
intravenously. Patients were prescribed zoledronate if 
they had a history of gastrointestinal )GI( problems, 
or developed GI complications within one month of 
starting treatment with alendronate. Apart from the 
latter patients, none of the patients was previously 
treated with bisphosphonates. Patients with poor or 
no compliance were excluded from the analysis and no 
data from such patients is, consequently, included in 
the analyses. 
This study was a random prospective audit of 
patients receiving alendronate or zoledronate for 
osteoporosis. Patients were given the choice of either 
oral alendronate, or i.v. zoledronate by the treating 
physician based on guidelines by the National Institute 
of Clinical Excellence )NICE( in UK, and also on their 
history of GI problems. Standard Arthritis Research 
patient leaflets on alendronate and zoledronate were 
given to the patients to aid in the decision-making 
on drug choice. All recruited patients were referred to 
the Radiology Department of the Royal London or 
St. Bartholomew’s Hospital for DEXA scans )Hologic 
Discovery QDR series, Waltham, MA, USA(. The 
study was authorized by the Clinical Audit Office of 
Barts Health HNS Trust and was carried out according 
to principles of the Helsinki Declaration. All patients 
signed consent forms before treatment, and their 
DEXA assessment to permit the release of de-identified 
demographic information.
Disclosure. Authors have no conflict of interest, and the 
work was not supported or funded by any drug company.
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Sites assessed by DEXA were total left hip and 
anterior-posterior spine )lumbar L1-L4( skeletal sites. 
The BMD at both sites was measured simultaneously at 
baseline, and then after one year, and then 2 years after 
starting treatment to obtain BMD and their T-scores. 
The BMD data on 116 of the 118 patients treated with 
alendronate was available after one year, and on all 118 
patients after 2 years of the study. For patients treated 
with zoledronate, BMD data was available on 113 
patients at one year, and on all 116 patients at 2 years of 
the study. All patients received oral daily calcium )≤1 g( 
and vitamin D )≤10 µg(. To ensure reproducibility of 
measurements and consistency of comparisons, short- 
and long-term precisions were measured on a daily 
basis. Short-term precision was assessed by scanning 
an anthromorphic spine phantom 20 times per day. 
The phantom contains a human-like spine segment 
made of calcium hydroxyapatite, enclosed in a block of 
water-simulant epoxy. This phantom has a BMD equal 
to 0.995 g/cm2. The phantom was used so that errors 
due to patient positioning did not affect measurements, 
and to evaluate performance of the scanner over a 
range of bone density values, and avoid operator and 
patient sources of error. The long-term precision of the 
scanner was determined on a daily basis using BMD 
measurements of the spine phantom as a routine part 
of quality control. Serum levels of calcium, phosphate, 
and alkaline phosphatase were routinely measured 
for the patients. All patients had values within the 
normal range for these tests. Demographic, clinical and 
lifestyle data were collected by interviewer-administered 
questionnaire at baseline, and after one-, and 2-years 
during DEXA scan appointments. Data collected 
consisted of age, lifestyle )smoking, alcohol consumption 
of more than 2 servings a day, and physical exercise(, 
personal and family history of fractures, ethnic origin, 
current medications, and history of prednisone use. 
Statistical analysis. Pearson’s chi-square test for 
dichotomous variables was used to compare the 
distribution of risk factors for osteoporosis between 
groups. Student’s t-test was applied to continuous 
variables. Changes in BMD between the 2 groups were 
compared using Student’s t-tests with the Statistical 
Package for Social Sciences version 19 software )IBM 
Corp., Armonk, NY, USA(. P<0.05 values were 
considered statistically significant.
Results. Demographic data on the patient cohort, 
their medical history and information on their lifestyle 
are summarized in Table 1. All recruited patients were 
interviewed by at least 2 members of the study team, and 
information recorded based on face-to-face interviews. 
There were no dropouts from the 234 patients whose 
data is included in this study, and all 118 patients 
treated with alendronate confirmed compliance with 
the treatment at interviews. However, it was not possible 
to verify patient statements on compliance by studying 
prescription refills. None of the patients treated with 
zoledronate had previously taken oral bisphosphonates 
for more than one month. Patients were excluded from 
treatment with alendronate only if they had a history of 
GI problem, or when prescribed alendronate show such 
problems within the first month of treatment. After the 
first month of starting treatment, none of the patients 
whose data are included in this study discontinued 
alendronate treatment to be treated with zoledronate. 
There were no statistically significant differences in 
perceived risk factors between the treatment groups 
)Table 1(. The mean age of all patients was 68.5 ± 12.5 
years )range: 46.5-72.6 years(. For patients treated with 
alendronate, the mean ± SEM ages was 67.5 ± 12.5, and 
for zoledronate the mean ± SEM ages was 69.6 ± 11.1. 
The proportion of post-menopausal women in each 
group was also not statistically different )Table 1(. 
However, the number of patients with fracture history 
was higher in the zoledronate-treated group compared 
with the alendronate group. This could suggest an 
element of unintended selection bias based on the higher 
fracture risk in the patients concerned. Nevertheless, 
this does not appear to have adversely influenced the 
analysis, and indeed, highlights the superior response in 
the zoledronate-treated group. At the end of the study, 
the mean duration of bisphosphonate treatment was 
23.8 ± 1.3 months. Baseline BMD in both treatment 
groups at the lumbar spine and total hip sites were 
comparable at the start of treatment )Table 2 & Figure 1(. 
Improvement in BMD in patients from the 2 treatment 
groups after 2 years was however, different. The BMD of 
the total hip decreased after 2 years in patients receiving 
alendronate by 0.4% from the baseline, whereas in 
the zoledronate-treated group, it increased by 0.8% 
)Figure 1A(. The BMD at the lumbar spine increased 
after 2 years in patients receiving alendronate by 3.6%, 
and zoledronate by 5.7% )Figure 1B(. The increase in 
BMD at both sites was significantly greater in patients 
receiving zoledronate compared with patients receiving 
alendronate )p=0.001(.
Discussion. This study demonstrates that treatment 
of osteoporosis patients with zoledronate once a year 
by i.v. injection is more effective than oral alendronate 
in increasing BMD at the hip and lumbar spine sites. 
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Table 2 - Mean bone mineral density )BMD( and T-score changes in the alendronate and zoledronate treated groups for 2 years.
Parameter
Before treatment After one year After 2 years
Alendronate Zoledronate Alendronate Zoledronate Alendronate Zoledronate
Lumbar spine
Mean ± SD, BMD, g/cm2   0.82 ± 0.1  0.75 ± 0.1 0.834 ± 0.1 0.772 ± 0.1  0.85 ± 0.1 0.793 ± 0.1
P-value   p=0.001 p=0.001 p=0.001 p=0.001
Mean T-score ± SD, % -2.21 ± 1.1 -2.81 ± 0.8    -2.1 ± 1.1 -2.65 ± 0.7 -1.98 ± 1.2 -2.45 ± 1.0
P-value p=0.3 p=0.02   p=0.02 p=0.02
Mean ± SD, BMD change   1.86 ± 0.4  2.89 ± 0.7  3.58 ± 0.4  5.69 ± 0.8
P-value  p=0.001 p=0.001 p=0.0001 p=0.001
Total hip
Mean ± SD, BMD, g/cm2   0.79 ± 0.1  0.75 ± 0.1 0.792 ± 0.2 0.760 ± 0.1 0.787 ± 0.1 0.756 ± 0.1
P-value p=0.02 p=0.01 p=0.01 p=0.01
Mean T-score ± SD -1.37 ± 0.9 -1.68 ± 0.9  -1.36 ± 1.1 -1.66 ± 0.8  -1.36 ± 0.8 -1.65 ± 0.9
P-value p=0.1 p=0.03 p=0.2 p=0.01
Mean ± SD, BMD change, %   0.25 ± 0.3    1.3 ± 0.4  -0.41 ± 0.4  0.78 ± 0.5
P-value p=0.01 p=0.03 p=0.0001 p=0.0001
SD - standard deviation. p-value indicates probability of statistical differences in mean BMD, mean T-scores, and % change in 
mean BMD for the 2 groups of patients after one-, and 2 years compared with baseline values )before treatment(
Table 1 - Demographic, clinical, and lifestyle data on the patient cohort studied for treatment efficacy of alendronate 
and zoledronate.
Parameter
Oral alendronate
70 mg once weekly, 
n=118
Intravenous  
zoledronate 5 mg/year, 
n=116
P-value
Age, mean ± standard deviation )SD( 67.5 ± 12.5   69.6 ± 11.1
Female, n (%)   98 )83.0( 100 )86.0(
Post-menopausal   92 )94.0(   98 )98.0(
Fracture history )vertebral and peripheral(, n )%(   19 )16.0(   28 )24.0(
Familial fracture, n )%(   16 )14.0(   17 )15.0(
Calcium intake )mg/day(, mean ± SD    692 ± 266   697 ± 259
Vitamin D, µg, mean ± SD  6.40 ± 2.9 6.45 ± 2.9 p=0.978
Prednisone (history), n (%) p=0.986
Ever used prednisone   21 )18.0(    23 )20.0 (
Currently use prednisone     9   )8.0(     5   )4.0(
Never used prednisone   88 )74.0(   88 )76.0(
History of medically-induced menopause, n )%(   10   )9.0(     9   )8.0( p=0.184
Been on hormone replacement therapy, n )%(     8   )7.0(     9   )8.0(
Low body mass, n )%(     6   )5.0(     9   )8.0( 
Lifestyle (history), n (%) p=0.731
Smoking   17 )15.0(   17 )15.0(
Alcohol consumption )more than 2 servings(     7   )6.0(     5   )5.0(
Physical )weight bearing exercises(   12 )10.0(   20 )17.0( 
Ancestral origin, n (%) p=0.988
Caucasian   92 )78.0(   98 )84.0(
Asian   20 )17.0(   14 )12.0(
Afro-Caribbean     6   )5.0(     4   )4.0(
p-values are statistical comparisons of data from the 2 groups of patients
Improvement in BMD in response to treatment with 
both agents was seen in both sets of patients after 
one year. However, BMD increased by a significantly 
greater magnitude in patients treated with zoledronate 
than patients treated with alendronate, suggesting 
superiority of the medication in improving BMD. 
The overall lower increase in BMD in the hip region 
compared with the lumbar spine is likely to be due to 
higher bone remodelling processes that are especially 
prominent in cancellous bone abundant in the lumbar 
spine.22 Differences in BMD between the 2 treatment 
groups, however, were not due to differences in baseline 
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demographics of the patients, such as age, gender, or 
menopausal status since these were not significantly 
different between both groups. 
The observations made in the study could be of 
clinical relevance with the small caveat that the findings 
could have been marginally influenced by selection 
bias, such as selecting patients with a higher fracture 
history, and also patients with GI intolerance to receive 
zoledronate rather than alendronate. However, positive 
effects on total hip BMD were observed after 2 years 
of treatment only in patients treated with zoledronate 
indicating that this agent is an effective alternative 
to alendronate in treating osteoporosis patients.
Although the data clearly shows a superior response of 
osteoporosis patients to treatment with zoledronate as 
compared with alendronate, we consider that treatment 
compliance of patients with alendronate have to also 
be taken into consideration although significant efforts 
were made in the current study to corroborate patient 
compliance. Thus, even mild adverse effects, such as 
GI intolerance and concerns regarding such side effects 
could have led to lack of adherence to, or persistence 
with treatment by some patients as observed by other 
investigators.5 This is important considering that there 
is some evidence to suggest that treatment compliance 
and persistence increases with reduced dosing and 
frequency of administration.23,24 Treatment with 
zoledronate presents the opportunity for once-yearly i.v. 
administration, and is reported to increase treatment-
adherence, especially in patients with polypharmacy.25 
Furthermore, improvement in adherence has been 
associated with a reduction in fracture risk.26 For these 
reasons, zoledronate has become often the preferred 
treatment of choice for those with GI intolerance to 
other treatments in the same class.24 However, patients 
with confirmed, or suspected poor, or no compliance 
were excluded from the analysis in our study when 
the information was available. Our results, therefore, 
provide good evidence that zoledronate has a notable 
superior effect on improving BMD at both assessed 
sites.
Incidences of serious adverse events were not 
recorded for either treatment-group in the current 
study. However, there is published evidence to indicate 
that orally-administered bisphosphonates are more 
likely to cause GI side effects than intravenous ones. 
Moreover, it can be inferred from the dose-route and 
regime used that patients are more likely to comply, 
and persist with zoledronate than with alendronate 
treatment. Nevertheless, incidences of acute-phase 
responses )APR( have been reported in patients treated 
with zoledronate.27 However, all APR components had 
their peak onset within one day, the median duration 
for 3 days, and severity rated as mild, or moderate in 
90% of patients. Vitamin D supplementation was 
reported to reduce the musculoskeletal pain element 
of APR, and deficiencies must, therefore, be corrected 
prior to administration of zoledronate.27,28 Calcium 
supplementation is also prescribed to counter the 
calcium-lowering effects of zoledronate through its 
effect on reducing bone turnover. It is also important 
to mention that renal deterioration progressing to renal 
failure has been observed by other investigators after an 
average of 56 days of zoledronate administration in some 
patients.29 Zoledronate is, therefore, contraindicated 
in patients with renal impairment, and all patients 
administered with zoledronate should be monitored for 
renal function regularly as a precautionary measure.
Figure 1 - Change in bone mineral density )BMD( from baseline to one and 2 years after treatment at: A( the hip; and B( the lumbar spine sites in patients 
with osteoporosis receiving oral alendronate, or zoledro≠nate. The BMD of the hip and lumbar spine were determined by dual energy x-ray 
absorptiometry scan at baseline )time 0(, and at one, and 2 years post treatment initiation. Percent changes in BMD values are presented as 
the mean for each group with their corresponding standard deviations. p=0.0001 in change in BMD from baseline to 2 years between patients 
treated with zoledronate compared with patients treated with alendronate in both sites after 2 years. 
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One limitation of the current study to be taken into 
consideration when treating patients is that assessment 
of the effects of alendronate and zoledronate involved 
measuring BMD, which is a surrogate measure of 
osteoporosis progression. However, the primary goal 
of treatment remains fracture reduction although 
low BMD remains the most recognized risk factor 
for predicting fractures.30 Nevertheless, extrapolation 
from these results to the wider clinical application of 
bisphosphonate should be undertaken with caution, 
since the data were collected over 2 years only. Studies 
for longer periods will be needed to assess the long-term 
efficacy and side effects of zoledronate. In addition, the 
use of biochemical bone turnover markers could be 
helpful in confirming our data, and in addition, could 
also help gain further insights into the mechanism of 
action of these therapeutic agents.
In summary, the current study confirms that 
treating osteoporosis patients with oral alendronate or 
with i.v. zoledronate is therapeutically beneficial for 
patients with osteoporosis. However, treatment with 
zoledronate offers therapeutic advantages. Therefore, 
zoledronate appears to be an acceptable alternative to 
oral bisphosphonates in the treatment of osteoporosis 
patients in general, and especially those who cannot 
tolerate oral bisphosphonates.
Acknowledgment. The authors gratefully acknowledge all staff 
at the Departments of Rheumatology and Radiology, The Royal London 
Hospital, Mile End Road, UK for their support with the study. 
References
 
  1. Sandhu SK, Hampson G. The pathogenesis, diagnosis, 
investigation and management of osteoporosis. J Clin Pathol 
2011; 64: 1042-1050.
  2. Harvey N, Dennison E, Cooper C. Osteoporosis: a lifecourse 
approach. J Bone Miner Res 2014; 29: 1917-1925.
  3. Cauley JA, Chalhoub D, Kassem AM, Fuleihan Gel-H. 
Geographic and ethnic disparities in osteoporotic fractures. Nat 
Rev Endocrinol 2014; 10: 338-351.
  4. Giger EV, Castagner B, Leroux JC. Biomedical applications of 
bisphosphonates. J Control Release 2013; 167: 175-188.
  5. Russell RG. Bisphosphonates: the first 40 years. Bone 2011; 49: 
2-19.
  6. Watts NB, Diab DL. Long-Term Use of Bisphosphonates in 
Osteoporosis. J Clin Endocrinol Metab 2010; 95: 1555-1565.
  7. Kanis JA, Reginster JY, Kaufman JM, Ringe JD, Adachi JD, 
Hiligsmann M, et al. A reappraisal of generic bisphosphonates 
in osteoporosis. Osteoporos Int 2012; 23: 213-221.
  8. Lee S, Glendenning P, Inderjeeth CA. Efficacy, side effects and 
route of administration are more important than frequency of 
dosing of anti-osteoporosis treatments in determining patient 
adherence: a critical review of published articles from 1970 to 
2009. Osteoporos Int 2011; 22: 741-753.
  9. Bauer DC, Schwartz A, Palermo L, Cauley J, Hochberg M, 
Santora A, et al. Fracture prediction after discontinuation of 4 
to 5 years of alendronate therapy: the FLEX study. JAMA Intern 
Med 2014; 174: 1126-1134.
10. Boonen S, Reginster JY, Kaufman JM, Lippuner K, Zanchetta 
J, Langdahl B, et al. Once-yearly zoledronic acid for treatment 
of postmenopausal osteoporosis. N Engl J Med 2012; 367: 
1714-1723.
11. Miller PD, Recker RR, Harris S, Silverman S, Felsenberg D, 
Reginster J, et al Long-term fracture rates seen with continued 
ibandronate treatment: pooled analysis of DIVA and MOBILE 
long-term extension studies. Osteoporos Int 2014; 25: 349-357. 
12. Donaldson MG, Palermo L, Ensrud KE, Hochberg MC, 
Schousboe JT, Cummings SR. Effect of alendronate for reducing 
fracture by FRAX score and femoral neck bone mineral density: 
the Fracture Intervention Trial. J Bone Miner Res 2012; 27: 
1804-1810.
13. Levis S, Theodore G. Summary of AHRQ’s comparative 
effectiveness review of treatment to prevent fractures in men 
and women with low bone density or osteoporosis: update of 
the 2007 report. J Manag Care Pharm 2012; 18 )4 Suppl B(: 
S1-S15.
14. McClung MR, Zanchetta JR, Racewicz A, Roux C, Benhamou 
CL, Man Z, et al. Efficacy and safety of risedronate 150-mg 
once a month in the treatment of postmenopausal osteoporosis: 
2-year data. Osteoporos Int 2013; 24:293-299.
15. Merck, Sharp and Dohme Limited. Fosamax: Summary of 
Product Characteristics 2010. [cited 22 October 2012]. Available 
from: http://www.medicines.org.uk/emc/medicine/1175/SPC/
Fosamax/
16. Bianchi G, Czerwinski E, Kenwright A, Burdeska A, Recker 
RR, Felsenberg D. Long-term administration of quarterly IV 
ibandronate is effective and well tolerated in postmenopausal 
osteoporosis: 5-year data from the DIVA study long-term 
extension. Osteoporos Int 2012; 23: 1769-1778.
17. Hongo M, Miyakoshi N, Kasukawa Y, Ishikawa Y, Shimada Y. 
Additive effect of elcatonin to risedronate for chronic back pain 
and quality of life in postmenopausal women with osteoporosis: 
a randomized controlled trial. J Bone Miner Metab 2015; 33: 
432-439.
18. Brown JP, Roux C, Ho PR, Bolognese MA, Hall J, Bone HG, 
et al. Denosumab significantly increases bone mineral density 
and reduces bone turnover compared with monthly oral 
ibandronate and risedronate in postmenopausal women who 
remained at higher risk for fracture despite previous suboptimal 
treatment with an oral bisphosphonate. Osteoporos Int 2014; 
25: 1953-1961.
19. Modi A, Siris ES, Steve Fan CP, Sajjan S. Gastrointestinal events 
among patients initiating osteoporosis therapy: a retrospective 
administrative claims database analysis. Clin Ther 2015; 37: 
1228-1234.
20. McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, 
Diez-Perez A, et al. Romosozumab in postmenopausal women 
with low bone mineral density. N Engl J Med 2014; 370: 
412-420.
21. Hadji P, Gamerdinger D, Spieler W, Kann PH, Loeffler H, 
Articus K, et al. Rapid Onset and Sustained Efficacy )ROSE( 
study: results of a randomised, multicentre trial comparing the 
effect of zoledronic acid or alendronate on bone metabolism 
in postmenopausal women with low bone mass. Osteoporos Int 
2012; 23: 625-633. 
22. Jiang E, Wang Z, Meng Q, Li S, Wang F, Shao G, et al. Study 
on bone density at various skeletal sites for the diagnosis of 
primary osteoporosis. Cell Biochem Biophys 2012; 64: 1-3. 
Intravenous and oral bisphosphonates ... Al-Bogami et al
1311www.smj.org.sa     Saudi Med J 2015; Vol. 36 )11(
23. Hadji P, Claus V, Ziller V, Intorcia M, Kostev K, Steinle 
T. GRAND: the German retrospective cohort analysis on 
compliance and persistence and the associated risk of fractures 
in osteoporotic women treated with oral bisphosphonates. 
Osteoporos Int 2012; 23: 223-231. 
24. Li L, Roddam A, Gitlin M, Taylor A, Shepherd S, Shearer 
A, et al. Persistence with osteoporosis medications among 
postmenopausal women in the UK General Practice Research 
Database. Menopause 2012; 19: 33-40. 
25. Pereira RM, Carvalho JF, Paula AP, Zerbini C, Domiciano DS, 
Gonçalves H, et al. Guidelines for the prevention and treatment 
of glucocorticoid-induced osteoporosis. Rev Bras Reumatol 
2012; 52: 580-593. English, Portuguese
26. Rietbrock S, Olson M, van Staa TP. The potential effects 
on fracture outcomes of improvements in persistence and 
compliance with bisphosphonates. QJM 2009;102: 35-42. 
27. Reid R, Gamble GD, Mesenbrink P, Lakatos P, Black DM. 
Characterization of and risk factors for the acute-phase response 
after zoledronic acid. J Clin Endocrinol Metab 2010; 95: 
4380-4387. 
28. Catalano A, Morabito N, Atteritano M, Basile G, Cucinotta 
D, Lasco A. Vitamin D Reduces musculoskeletal pain after 
infusion of zoledronic acid for postmenopausal osteoporosis. 
Calcif Tissue Int 2012; 90: 279-285. 
29. Diel IJ, Weide R, Köppler H, Antràs L, Smith M, Green J, et 
al. Risk of renal impairment after treatment with ibandronate 
versus zoledronic acid: a retrospective medical records review. 
Support Care Cancer 2009; 17: 719-725. 
30. Unnanuntana A, Gladnick BP, Donnelly E, Lane JM. The 
assessment of fracture risk. J Bone Joint Surg Am 2010; 92: 
743-753. 
Statistics
Excerpts from the Uniform Requirements for Manuscripts Submitted to 
Biomedical Journals updated November 2003. 
Available from www.icmje.org
Describe statistical methods with enough detail to enable a knowledgeable reader 
with access to the original data to verify the reported results. When possible, 
quantify findings and present them with appropriate indicators of measurement 
error or uncertainty )such as confidence intervals(. Avoid relying solely on 
statistical hypothesis testing, such as the use of P values, which fails to convey 
important information about effect size. References for the design of the study 
and statistical methods should be to standard works when possible )with pages 
stated(. Define statistical terms, abbreviations, and most symbols. Specify the 
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